scholarly journals Bladder Tumor Heterogeneity: The Impact on Clinical Treatment

2015 ◽  
Vol 95 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Chao Chen ◽  
Xiang Jie Qi ◽  
Yan Wei Cao ◽  
Yong Hua Wang ◽  
Xue Cheng Yang ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Treatment Failure ◽  
Tumor Cells ◽  
Cancer Progression ◽  
Tumor Heterogeneity ◽  
Bladder Tumor ◽  
Gene Sequencing ◽  
Generation Model ◽  
And Control ◽  
The Impact

Bladder cancer relapse and treatment failure in most patients have often been attributed to chemoresistance in tumor cells and metastasis. Emerging evidence indicates that tumor heterogeneity may play an equally important role and extends to virtually all measurable properties of cancer cells. Although the idea of tumor heterogeneity is not new, little attention has been paid to applying it to understand and control bladder cancer progression. With the development of biotechnology, such as Gene sequencing, recent advances in understanding its generation model, original basis, consequent problems, and derived therapies provide great potential for tumor heterogeneity to be considered a new insight in the treatment of bladder cancers.

scholarly journals MicroRNAs and Their Influence on the ZEB Family: Mechanistic Aspects and Therapeutic Applications in Cancer Therapy

Biomolecules ◽  
2020 ◽  
Vol 10 (7) ◽  
pp. 1040 ◽  
Author(s):  
Milad Ashrafizadeh ◽  
Hui Li Ang ◽  
Ebrahim Rahmani Moghadam ◽  
Shima Mohammadi ◽  
Vahideh Zarrin ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Cancer Therapy ◽  
Signaling Pathways ◽  
Tumor Cells ◽  
Cancer Progression ◽  
Epithelial Mesenchymal Transition ◽  
Migration And Invasion ◽  
Circular Rnas ◽  
Mesenchymal Transition ◽  
The Impact

Molecular signaling pathways involved in cancer have been intensively studied due to their crucial role in cancer cell growth and dissemination. Among them, zinc finger E-box binding homeobox-1 (ZEB1) and -2 (ZEB2) are molecules that play vital roles in signaling pathways to ensure the survival of tumor cells, particularly through enhancing cell proliferation, promoting cell migration and invasion, and triggering drug resistance. Importantly, ZEB proteins are regulated by microRNAs (miRs). In this review, we demonstrate the impact that miRs have on cancer therapy, through their targeting of ZEB proteins. MiRs are able to act as onco-suppressor factors and inhibit the malignancy of tumor cells through ZEB1/2 down-regulation. This can lead to an inhibition of epithelial-mesenchymal transition (EMT) mechanism, therefore reducing metastasis. Additionally, miRs are able to inhibit ZEB1/2-mediated drug resistance and immunosuppression. Additionally, we explore the upstream modulators of miRs such as long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), as these regulators can influence the inhibitory effect of miRs on ZEB proteins and cancer progression.

scholarly journals Classifying bladder cancer subtypes

2018 ◽  
Author(s):  
Cihan Kaya ◽  
Nicolas Arcenio Pabon
Keyword(s):  
Bladder Cancer ◽  
Mrna Expression ◽  
Tumor Cells ◽  
Bladder Tumor ◽  
Expression Profiles ◽  
The United States ◽  
Micro Rna ◽  
The Cancer Genome Atlas ◽  
Test Accuracy ◽  
Genetic Features

AbstractUrothelial carcinoma of the bladder is is estimated to have killed over 16,000 people in the United States in 2016. Like breast cancer, bladder cancer is a heterogeneous disease, and characterization of it’s various subtypes can be useful for forecasting prognosis and treatment efficacy. According to The Cancer Genome Atlas (TCGA) project, the mRNA expression profiles of bladder tumours can be used to cluster the tumors into four different categories: I - Papillary-like, II ‐Luminal A, III - basal/squamous-like, and IV - other (similar to III). However it is not clear whether these mRNA expression based clusters correlate with other molecular and genetic features of the tumor cells. In other words, do differences in mRNA expression profile contain the same information as differences in protein expression, micro RNA (miRNA) expression, copy number variation and somatic mutation data. We tried to recreate mRNA based bladder tumor clusters from other multi-omic data for 328 bladder cancer tumor samples using a special deep and wide belief network composed of restricted Boltzmann machines and a multilayer perceptron. For 10-fold cross validation, we got 79% average test accuracy which implies that that differences in mRNA expression between bladder tumor cells can be reliably, though not perfectly, inferred from different molecular and genetic features of the tumors.

scholarly journals Multifaced roles of PLAC8 in cancer

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Misha Mao ◽  
Yifan Cheng ◽  
Jingjing Yang ◽  
Yongxia Chen ◽  
Ling Xu ◽  
...  
Keyword(s):  
Cell Growth ◽  
Tumor Cells ◽  
Cancer Cell ◽  
Cancer Progression ◽  
Molecular Mechanisms ◽  
Molecular Function ◽  
Cancer Cell Growth ◽  
The Impact ◽  
Functional Output

AbstractThe role of PLAC8 in tumorigenesis has been gradually elucidated with the development of research. Although there are common molecular mechanisms that enforce cell growth, the impact of PLAC8 is varied and can, in some instances, have opposite effects on tumorigenesis. To systematically understand the role of PLAC8 in tumors, the molecular functions of PLAC8 in cancer will be discussed by focusing on how PLAC8 impacts tumorigenesis when it arises within tumor cells and how these roles can change in different stages of cancer progression with the ultimate goal of suppressing PLAC8-relevant cancer behavior and related pathologies. In addition, we highlight the diversity of PLAC8 in different tumors and its functional output beyond cancer cell growth. The comprehension of PLAC8’s molecular function might provide new target and lead to the development of novel anticancer therapies.

Increase in Circulating Tumor Cells in Invasive Bladder Cancer After Transurethral Resection of Bladder Tumor

2020 ◽  
Vol 40 (8) ◽  
pp. 4299-4307
Author(s):  
NOBUHIRO HAGA ◽  
KAZUNA TSUBOUCHI ◽  
HIROKO MARUTA ◽  
TOMOYUKI KOGUCHI ◽  
SEIJI HOSHI ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Transurethral Resection ◽  
Bladder Tumor ◽  
Invasive Bladder Cancer

scholarly journals Leupaxin Promotes Bladder Cancer Proliferation, Metastasis, and Angiogenesis Through the PI3K/AKT Pathway

2018 ◽  
Vol 47 (6) ◽  
pp. 2250-2260 ◽  
Author(s):  
Teng Hou ◽  
Lijie Zhou ◽  
Longwang Wang ◽  
Gallina Kazobinka ◽  
Yumao Chen ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Cells ◽  
Cancer Progression ◽  
Akt Pathway ◽  
Advanced Tumor Stage ◽  
Large Tumor ◽  
Advanced Tumor ◽  
Bladder Cancer Cells ◽  
The Impact

Background/Aims: Leupaxin (LPXN) is a member of the paxillin protein family. Several studies have reported that LPXN regulates cancer development; however, the role of LPXN in bladder cancer remains unknown. Methods: The expression of LPXN in bladder cancer cells and tissues was determined by real-time PCR, western blotting, and immunohistochemistry, respectively. The biological role of LPXN in bladder cancer cell proliferation, invasion, and angiogenesis was explored both in vitro and in vivo. Results: LPXN expression was elevated in bladder cancer tissues and cell lines compared to adjacent non-tumor tissues and normal urothelial cells. High LPXN expression was correlated with large tumor size, advanced tumor stage, and poor survival in bladder cancer patients. Overexpression of LPXN significantly promoted the proliferation, invasion, and angiogenesis of bladder cancer cells, while suppressing LPXN had the opposite effects. The impact on tumor progression was abolished by inhibiting PI3K/ AKT signaling pathway. We further demonstrated that LPXN probably up-regulated S100P via the PI3K/AKT pathway. Conclusions: LPXN may facilitate bladder cancer progression by upregulating the expression of S100P via PI3K/AKT pathway. These results provide a novel insight into the role of LPXN in tumorigenesis and progression of bladder cancer and potential therapeutic target of bladder cancer.

scholarly journals Non coding RNAs as the critical factors in chemo resistance of bladder tumor cells

2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Amir Sadra Zangouei ◽  
Hamid Reza Rahimi ◽  
Majid Mojarrad ◽  
Meysam Moghbeli
Keyword(s):  
Bladder Cancer ◽  
Tumor Cells ◽  
Bladder Tumor ◽  
Distant Metastases ◽  
Developed Countries ◽  
Main Body ◽  
Non Coding Rnas ◽  
Chemotherapeutic Treatment ◽  
Muscle Invasive ◽  
Muscle Invasion

Abstract Background Bladder cancer (BCa) is the ninth frequent and 13th leading cause of cancer related deaths in the world which is mainly observed among men. There is a declining mortality rates in developed countries. Although, the majority of BCa patients present Non-Muscle-Invasive Bladder Cancer (NMIBC) tumors, only 30% of patients suffer from muscle invasion and distant metastases. Radical cystoprostatectomy, radiation, and chemotherapy have proven to be efficient in metastatic tumors. However, tumor relapse is observed in a noticeable ratio of patients following the chemotherapeutic treatment. Non-coding RNAs (ncRNAs) are important factors during tumor progression and chemo resistance which can be used as diagnostic and prognostic biomarkers of BCa. Main body In present review we summarized all of the lncRNAs and miRNAs associated with chemotherapeutic resistance in bladder tumor cells. Conclusions This review paves the way of introducing a prognostic panel of ncRNAs for the BCa patients which can be useful to select a proper drug based on the lncRNA profiles of patients to reduce the cytotoxic effects of chemotherapy in such patients.

scholarly journals Tumor Heterogeneity and Consequences for Bladder Cancer Treatment

Cancers ◽  
2021 ◽  
Vol 13 (21) ◽  
pp. 5297
Author(s):  
Etienne Lavallee ◽  
John P. Sfakianos ◽  
David J. Mulholland
Keyword(s):  
Bladder Cancer ◽  
Stress Responses ◽  
Tumor Heterogeneity ◽  
Immune Cell ◽  
De Novo ◽  
Epithelial Tumor ◽  
Cancer Management ◽  
Impact On Treatment ◽  
Tumor Types ◽  
The Impact

Acquired therapeutic resistance remains a major challenge in cancer management and associates with poor oncological outcomes in most solid tumor types. A major contributor is tumor heterogeneity (TH) which can be influenced by the stromal; immune and epithelial tumor compartments. We hypothesize that heterogeneity in tumor epithelial subpopulations—whether de novo or newly acquired—closely regulate the clinical course of bladder cancer. Changes in these subpopulations impact the tumor microenvironment including the extent of immune cell infiltration and response to immunotherapeutics. Mechanisms driving epithelial tumor heterogeneity (EpTH) can be broadly categorized as mutational and non-mutational. Mechanisms regulating lineage plasticity; acquired cellular mutations and changes in lineage-defined subpopulations regulate stress responses to clinical therapies. If tumor heterogeneity is a dynamic process; an increased understanding of how EpTH is regulated is critical in order for clinical therapies to be more sustained and durable. In this review and analysis, we assess the importance and regulatory mechanisms governing EpTH in bladder cancer and the impact on treatment response.

scholarly journals The Dependence between Urinary Levels of Angiogenesis Factors, 8-Iso-prostaglandin F2α, ɣ-Synuclein, and Interleukin-13 in Patients with Bladder Cancer: A Pilot Study

2020 ◽  
Vol 2020 ◽  
pp. 1-11
Author(s):  
Beata Szymańska ◽  
Ewa Sawicka ◽  
Michał Matuszewski ◽  
Janusz Dembowski ◽  
Agnieszka Piwowar
Keyword(s):  
Oxidative Stress ◽  
Bladder Cancer ◽  
Cancer Progression ◽  
Prostaglandin F2α ◽  
Invasive Bladder Cancer ◽  
Enzyme Linked Immunosorbent Assay ◽  
Low Grade ◽  
Interleukin 13 ◽  
Urinary Levels ◽  
The Impact

During the last decade, a significant increase in the incidence of bladder cancer (BC) has been observed. Angiogenesis plays a key role in the process of tumor growth and metastasis. Additionally, the participation of oxidative stress and chronic inflammation in BC pathogenesis is indicated. The aim of the study was to evaluate the urinary levels of parameters of angiogenesis, stimulating angiogenin (ANG) and inhibiting angiostatin (ANGST), 8-iso-prostaglandin F2α (8-iso-PGF2α) as a marker of oxidative stress, ɣ-synuclein (SNCG) as a cancer progression parameter, and interleukin-13 (IL-13) as an anti-inflammatory immunomodulator. The levels of ANG, ANGST, 8-iso-PGF2α, SNCG, and IL-13 in the urine of BC patients and healthy controls were measured by the enzyme-linked immunosorbent assay. These parameters were examined in the whole group of BC patients and in subgroups depending on the clinical stage: nonmuscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC); histopathologic malignancy: low grade (LG) and high grade (HG) and in primary and recurrent BC. Significantly, higher urinary parameters were found in BC patients in comparison to controls. Levels of all parameters increased with the development of cancer, with the exception of 8-iso-prostaglandin F2α, in which the level was higher in the early stages of the disease, but these differences were not statistically significant. Some correlations have been demonstrated between parameters in BC patients. Based on the receiver operating characteristic curves, ANG and ANGST had the best diagnostic value for BC. The obtained results indicate the important role of the examined parameters of angiogenesis, oxidative stress, and inflammation in the pathogenesis and development of BC. It is reasonable to continue research in order to thoroughly assess the impact of various associated processes on the course of BC. It is also important to carry out similar tests in patients with other urological diseases.

Sign in / Sign up

Export Citation Format

Share Document